Umeclidinium bromide, sold under the brand name Incruse Ellipta among others, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol),[5][6][7] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.[8]

It is on the World Health Organization's List of Essential Medicines.[9] In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[10][11]

References

  1. ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  2. ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.
  3. ^ a b c "Incruse Ellipta- umeclidinium aerosol, powder". DailyMed. 13 December 2023. Retrieved 28 March 2025.
  4. ^ "Rolufta Ellipta (previously Rolufta)". European Medicines Agency (EMA). 20 March 2017. Retrieved 28 March 2025.
  5. ^ "Anoro Ellipta- umeclidinium bromide and vilanterol trifenatate powder". DailyMed. 2 June 2023. Retrieved 28 March 2025.
  6. ^ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282.
  7. ^ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
  8. ^ "Trelegy Ellipta- fluticasone furoate, umeclidinium bromide and vilanterol trifenatate powder". DailyMed. 2 June 2023. Retrieved 28 March 2025.
  9. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  10. ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  11. ^ "Umeclidinium - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.


Allikas: http://en.wikipedia.org/wiki/Umeclidinium
No tags for this post.